Ulipristal acetate before high complexity endoscopic (hysteroscopic, laparoscopic) myomectomy – a mini-review
Uterine myomas (fibromas, leiomyomas) are the most common tumours in women, and their clinical signs and symptoms are presented by 25-40% of patients with these benign tumours. According to current guidelines, the armamentarium for myoma management consists of: medical therapy (GnRH, SPRMs), non-s...
Main Author: | Włodzimierz Baranowski |
---|---|
Format: | Article |
Language: | English |
Published: |
Termedia Publishing House
2017-02-01
|
Series: | Menopause Review |
Subjects: | |
Online Access: | https://www.termedia.pl/Ulipristal-acetate-before-high-complexity-endoscopic-hysteroscopic-laparoscopic-myomectomy-a-mini-review,4,29352,1,1.html |
Similar Items
-
Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids
by: Iwona Szydłowska, et al.
Published: (2020-01-01) -
The Use of ulipristal acetate (Esmya) prior to laparoscopic myomectomy: Help or hindrance?
by: Rebecca Mallick, et al.
Published: (2019-01-01) -
CLINICAL AND MORPHOLOGICAL RATIONALE FOR THE ULIPRISTAL ACETATE PRE-OPERATION TREATMENT BEFORE ORGANPRESERVING OPERATIONS IN MYOMAS UTERUS PATIENTS WITH THE INTRAUTERINE BLEEDING AND ANAEMIA
by: A. V. Kozachenko, et al.
Published: (2017-10-01) -
Laparoscopic myomectomy instead of hysteroscopic myomectomy for large submucous fibroids
by: Chin-Jung Wang, et al.
Published: (2013-08-01) -
Markers of Cellular Proliferation, Apoptosis, Estrogen/Progesterone Receptor Expression and Fibrosis in Selective Progesterone Receptor Modulator (Ulipristal Acetate)-Treated Uterine Fibroids
by: Iwona Szydłowska, et al.
Published: (2021-02-01)